FITC Anti-CD23 antibody [007]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

CD23 also known as Fc epsilon receptor II (FcεRII) or BU38 is a type II integral membrane protein with a molecular mass of approximately 45 kDa. It is expressed mainly on B cells but also appears on various other cell types such as macrophages eosinophils and Langerhans cells. CD23 expression occurs in both soluble and membrane-bound forms. The protein consists of a lectin-like extracellular domain a short transmembrane domain and a cytoplasmic tail.

Biological function summary

CD23 facilitates several immune functions including the regulation of immunoglobulin E (IgE) production and its receptor-mediated endocytosis. It has a role in cell adhesion growth and differentiation. CD23 exists independently localizing primarily to the surface of CD23-positive cells. Furthermore this protein influences the release and activity of various cytokines impacting both innate and adaptive immunity.

Pathways

CD23 plays central roles in IgE-mediated immune responses and allergic reactions. It is importantly involved in the synthesis and regulation of IgE connecting it to the IgE signaling pathway and immune system pathways. CD23 interacts with IgE and its receptors which include the high-affinity receptor FcεRI forming an interface between the antigen and immune effector functions. Additionally CD23 participates in pathways that involve immune response modulation and inflammation prevention.

Associated diseases and disorders

CD23 is most notably associated with allergic diseases such as asthma and allergic rhinitis due to its role in IgE regulation. It is also linked to chronic lymphocytic leukemia (CLL) in which CD23 serves as a marker for disease progression. In CLL interactions involving CD23 and related proteins such as BCMA and BAFF have been studied to better understand the disorder and its treatment. Anti-CD23 antibodies have been used as both diagnostic tools and therapeutic agents to target CD23-positive cells in these diseases.